These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28689663)

  • 21. The dynamic landscape of liver transplant in the era of effective hepatitis C virus therapy.
    Verna EC
    Hepatology; 2017 Mar; 65(3):763-766. PubMed ID: 28093781
    [No Abstract]   [Full Text] [Related]  

  • 22. [Hepatitis C virus ten years after its discovery].
    Bralet MP; Dhumeaux D; Zafrani ES
    Ann Pathol; 1999 Dec; 19(6):499-512. PubMed ID: 10617807
    [No Abstract]   [Full Text] [Related]  

  • 23. The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.
    Kwo PY; Shiffman ML; Bernstein DE
    Am J Gastroenterol; 2018 Jan; 113(1):2-4. PubMed ID: 29134963
    [No Abstract]   [Full Text] [Related]  

  • 24. The Promise of Direct-Acting Antiviral Therapies to Improve Care and Outcomes in Patients With Cancer Who Have Chronic Hepatitis C Infection.
    Koullias Y; Hammond SP
    J Oncol Pract; 2019 Dec; 15(12):639-640. PubMed ID: 31825757
    [No Abstract]   [Full Text] [Related]  

  • 25. Reply to the comment "infection with hepatitis C virus, interferon α and lupus: an odd association".
    Auñón P; Morales E
    Nefrologia; 2015; 35(5):507-8. PubMed ID: 26306965
    [No Abstract]   [Full Text] [Related]  

  • 26. Editorial: hepatitis C direct acting anti-viral agents and the kidney.
    Hussaini T; Yoshida EM
    Aliment Pharmacol Ther; 2017 Aug; 46(3):378-379. PubMed ID: 28677286
    [No Abstract]   [Full Text] [Related]  

  • 27. Societal Perspectives and Patient/Public Involvement in Direct-Acting Antiviral Agent Coverage of Hepatitis C Treatment in the United States.
    Liu X; Lee JL; Yoo JW
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1814-1815. PubMed ID: 28606844
    [No Abstract]   [Full Text] [Related]  

  • 28. [Expert advices for evaluating clinical trials of direct-acting antiviral agents for hepatitis C].
    Research Group for New Drug's Clinical Evalutaion of Critical Diseases and Platform Construction of Integrated Technology
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):161-4. PubMed ID: 27095756
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapeutic update in hepatitis C].
    Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist.
    Perrella A; Rinaldi L; Galeota-Lanza A; Izzi A
    Am J Gastroenterol; 2018 Aug; 113(8):1251. PubMed ID: 29686274
    [No Abstract]   [Full Text] [Related]  

  • 31. General practitioners require more support to prescribe direct acting antiviral therapy for hepatitis C.
    Sud R; Tiwari N; Forner P; Dowdell L; Freiman J; Zekry A
    Intern Med J; 2018 Jan; 48(1):105-106. PubMed ID: 29314510
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatitis C treatment – yesterday, tomorrow and ….
    Weitzel C
    Med Monatsschr Pharm; 2017 Apr; 40(4):147-50. PubMed ID: 29952162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.
    Alqahtani S; Sulkowski M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):825-43. PubMed ID: 26600222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy.
    Marchan-Lopez A; Dominguez-Dominguez L; Kessler-Saiz P; Jarrin-Estupiñan ME
    J Hepatol; 2016 Mar; 64(3):752-3. PubMed ID: 26682727
    [No Abstract]   [Full Text] [Related]  

  • 35. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: Do direct-acting antiviral regimens matter?
    Ji F; Yeo YH; Wei MT; Wei B; Dang S; Li Z; Nguyen MH
    Hepatology; 2018 Mar; 67(3):1180-1182. PubMed ID: 29194694
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hepatitis c virus infections. New therapeutic treatments].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 2007 Nov; 30(11):422-3. PubMed ID: 18062337
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of Hepatitis C Virus in HIV-Coinfected Individuals in Real-world Clinical Settings: Results From 2 Large HIV Care Clinics.
    Rowan SE; Rogers M; Bayer J; Smith L; Gardner EM; Johnson S; Langness J
    Clin Infect Dis; 2016 Oct; 63(7):994-5. PubMed ID: 27369322
    [No Abstract]   [Full Text] [Related]  

  • 38. The Elevation of Hepatic Venous Pressure Gradient After Sustained Virologic Response in Hepatitis C Virus-Related Cirrhosis.
    Lo GH
    Gastroenterology; 2018 Apr; 154(5):1551. PubMed ID: 29526726
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-Effective but Unaffordable and Unequal Hepatitis C Treatment in the US.
    Liu X; Shen JJ; Lee JL; Yoo JW
    Am J Gastroenterol; 2017 Nov; 112(11):1749. PubMed ID: 29109499
    [No Abstract]   [Full Text] [Related]  

  • 40. Response to Perrella et al.
    Kwo PY; Shiffman ML; Bernstein DE
    Am J Gastroenterol; 2018 Aug; 113(8):1251-1252. PubMed ID: 29915397
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.